Working... Menu
Trial record 16 of 277 for:    Non-alcoholic Steatohepatitis | United States

Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00699036
Recruitment Status : Unknown
Verified June 2009 by Brooke Army Medical Center.
Recruitment status was:  Recruiting
First Posted : June 17, 2008
Last Update Posted : June 19, 2009
Information provided by:
Brooke Army Medical Center

Brief Summary:
The purpose of this study is to evaluate the efficacy of rosiglitazone alone compared with rosiglitazone plus metformin or rosiglitazone plus losartan in the treatment of biopsy proven nonalcoholic steatohepatitis (NASH). This study was designed to answer the question: are there differences in the efficacy (as measured by histopathology and insulin resistance) of three different therapeutic modalities used to treat NASH?

Condition or disease Intervention/treatment Phase
Nonalcoholic Steatohepatitis Nonalcoholic Fatty Liver Disease Drug: avandia Drug: metformin Drug: losartan Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 165 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rosiglitazone Versus Rosiglitazone and Metformin (Avandamet) Versus Combination Rosiglitazone and Losartan in the Treatment of Nonalcoholic Steatohepatitis (NASH). A Prospective, Open-Label, Randomized Trial
Study Start Date : April 2007
Estimated Primary Completion Date : July 2009
Estimated Study Completion Date : August 2009

Arm Intervention/treatment
Experimental: 1
Drug: avandia
4 mg twice daily

Experimental: 2
avandia plus metformin
Drug: avandia
4 mg twice daily

Drug: metformin
500 mg twice daily for 48 weeks

Experimental: 3
avandia plus losartan
Drug: avandia
4 mg twice daily

Drug: losartan
losartan 50 mg once daily

Primary Outcome Measures :
  1. liver biopsy histologic improvement [ Time Frame: end of study ]

Secondary Outcome Measures :
  1. serum transaminases [ Time Frame: throughout study (ongoing) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients between 18-70 years old
  2. Negative urine pregnancy test in females
  3. History of elevated liver associated enzymes (ALT > 40)
  4. Liver biopsy within 1 year of screening in this study that shows histopathologic findings consistent with NASH

Exclusion Criteria:

  1. ALT greater than three times normal
  2. NYHA class 3 or 4 heart failure
  3. Any congestive heart failure patient on insulin
  4. Patients on one of the 3 study drugs within the past 3 months prior to enrollment
  5. Alcohol consumption >20 gm/day in a female and > 30 gm/day in a male
  6. Evidence of co-existent chronic liver disease to include viral hepatitis, Wilson's disease, autoimmune hepatitis, hemochromatosis, primary biliary cirrhosis, or primary sclerosing cholangitis
  7. Serum creatinine on initial screening of greater than 1.4
  8. Known hypersensitivity to rosiglitazone, metformin, or losartan
  9. Known history of diabetic ketoacidosis
  10. Female that is breastfeeding
  11. Insulin dependent diabetic

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00699036

Layout table for location information
United States, Texas
Brooke Army Medical Center Recruiting
San Antonio, Texas, United States, 78234
Contact: Dawn M Torres, MD    210-916-5649      
Principal Investigator: Dawn M Torres, MD         
Sub-Investigator: Stephen A Harrison, MD         
Sponsors and Collaborators
Brooke Army Medical Center
Layout table for investigator information
Principal Investigator: Dawn M Torres, MD Brooke Army Medical Center

Layout table for additonal information
Responsible Party: Dawn M. Torres, MD. Principal Investigator, Brooke Army Medical Center Identifier: NCT00699036     History of Changes
Other Study ID Numbers: C.2007.066
First Posted: June 17, 2008    Key Record Dates
Last Update Posted: June 19, 2009
Last Verified: June 2009

Keywords provided by Brooke Army Medical Center:
nonalcoholic steatohepatitis (NASH)
fatty liver
insulin resistance

Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action